8 news items
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEVA
1 Jun 24
. For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of falls when
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEVA
1 Jun 24
).
Clinician-reported TD severity and impact is assessed using the IMPACT-TD scale, the AIMS (Abnormal Involuntary Movement Scale) and the CGIS-TD (Clinical
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
TEVA
30 May 24
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
TEVA
29 May 24
should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing
Teva Pharmaceuticals And Medincell Say Phase 3 Efficacy Results From SOLARIS Trial For Schizophrenia Showed That TEV-'749 Met Its Primary Endpoint As Measured By A Change In The PANSS Total Score From Baseline After 8 Weeks Compared To Placebo
TEVA
8 May 24
groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total score, a widely used assessment tool for schizophrenia symptom
pff4mw4ebu24t6qat2zrqginfsnguootx6ll
TEVA
8 May 24
in the Positive and Negative Syndrome Scale (PANSS) total score, a widely used assessment tool for schizophrenia symptom severity
tcp9gowq 1ry23uejz7x6
TEVA
2 May 24
Based on an assessment of the Company's economic impact, Teva's generic medicines contributed to $40.9 billion
h27uo09jokrq95
TEVA
6 Apr 24
):
(Encore) Occupational Impact of Tardive Dyskinesia (TD): a Cross-Sectional, International Survey Assessing the Perceptions and Experiences of Patients
- Prev
- 1
- Next